198 related articles for article (PubMed ID: 37794185)
1. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
Baumgartner CK; Ebrahimi-Nik H; Iracheta-Vellve A; Hamel KM; Olander KE; Davis TGR; McGuire KA; Halvorsen GT; Avila OI; Patel CH; Kim SY; Kammula AV; Muscato AJ; Halliwill K; Geda P; Klinge KL; Xiong Z; Duggan R; Mu L; Yeary MD; Patti JC; Balon TM; Mathew R; Backus C; Kennedy DE; Chen A; Longenecker K; Klahn JT; Hrusch CL; Krishnan N; Hutchins CW; Dunning JP; Bulic M; Tiwari P; Colvin KJ; Chuong CL; Kohnle IC; Rees MG; Boghossian A; Ronan M; Roth JA; Wu MJ; Suermondt JSMT; Knudsen NH; Cheruiyot CK; Sen DR; Griffin GK; Golub TR; El-Bardeesy N; Decker JH; Yang Y; Guffroy M; Fossey S; Trusk P; Sun IM; Liu Y; Qiu W; Sun Q; Paddock MN; Farney EP; Matulenko MA; Beauregard C; Frost JM; Yates KB; Kym PR; Manguso RT
Nature; 2023 Oct; 622(7984):850-862. PubMed ID: 37794185
[TBL] [Abstract][Full Text] [Related]
2. Small molecule. Big biology. Dual phosphatase inhibitor enters the immunotherapy fray.
Wilson NS; Huntington ND
Immunol Cell Biol; 2024 Jan; 102(1):8-11. PubMed ID: 37982351
[TBL] [Abstract][Full Text] [Related]
3. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
[TBL] [Abstract][Full Text] [Related]
4. A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity.
Liang S; Tran E; Du X; Dong J; Sudholz H; Chen H; Qu Z; Huntington ND; Babon JJ; Kershaw NJ; Zhang ZY; Baell JB; Wiede F; Tiganis T
Nat Commun; 2023 Jul; 14(1):4524. PubMed ID: 37500611
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy.
Zhu Z; Tang R; Huff S; Kummetha IR; Wang L; Li N; Rana TM
Cancer Res Commun; 2023 Jan; 3(1):119-129. PubMed ID: 36968224
[TBL] [Abstract][Full Text] [Related]
6. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Zhou T; Damsky W; Weizman OE; McGeary MK; Hartmann KP; Rosen CE; Fischer S; Jackson R; Flavell RA; Wang J; Sanmamed MF; Bosenberg MW; Ring AM
Nature; 2020 Jul; 583(7817):609-614. PubMed ID: 32581358
[TBL] [Abstract][Full Text] [Related]
7. Nepetin Acts as a Multi-Targeting Inhibitor of Protein Tyrosine Phosphatases Relevant to Insulin Resistance.
Yoon SY; Ahn D; Kim JK; Seo SO; Chung SJ
Chem Biodivers; 2022 Jan; 19(1):e202100600. PubMed ID: 34725898
[TBL] [Abstract][Full Text] [Related]
8. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
9. Little ones can do big things: Small molecule inhibitors target PTPN2/PTPN1 for tumor immunotherapy.
Wang J; Qin S; Zhang A
MedComm (2020); 2024 Jun; 5(6):e567. PubMed ID: 38817652
[TBL] [Abstract][Full Text] [Related]
10. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors.
Zheng J; Zhang Z; Ding X; Sun D; Min L; Wang F; Shi S; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
Eur J Med Chem; 2024 Apr; 270():116390. PubMed ID: 38604096
[TBL] [Abstract][Full Text] [Related]
12. Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.
Katkeviciute E; Hering L; Montalban-Arques A; Busenhart P; Schwarzfischer M; Manzini R; Conde J; Atrott K; Lang S; Rogler G; Naschberger E; Schellerer VS; Stürzl M; Rickenbacher A; Turina M; Weber A; Leibl S; Leventhal GE; Levesque M; Boyman O; Scharl M; Spalinger MR
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33001862
[TBL] [Abstract][Full Text] [Related]
13. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Manguso RT; Pope HW; Zimmer MD; Brown FD; Yates KB; Miller BC; Collins NB; Bi K; LaFleur MW; Juneja VR; Weiss SA; Lo J; Fisher DE; Miao D; Van Allen E; Root DE; Sharpe AH; Doench JG; Haining WN
Nature; 2017 Jul; 547(7664):413-418. PubMed ID: 28723893
[TBL] [Abstract][Full Text] [Related]
14. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
15. PTPN2 regulates the generation of exhausted CD8
LaFleur MW; Nguyen TH; Coxe MA; Miller BC; Yates KB; Gillis JE; Sen DR; Gaudiano EF; Al Abosy R; Freeman GJ; Haining WN; Sharpe AH
Nat Immunol; 2019 Oct; 20(10):1335-1347. PubMed ID: 31527834
[TBL] [Abstract][Full Text] [Related]
16. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
17. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
18. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
19. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
Li Y; Zhang Y; Cao G; Zheng X; Sun C; Wei H; Tian Z; Xiao W; Sun R; Sun H
J Hematol Oncol; 2021 Jun; 14(1):100. PubMed ID: 34174928
[TBL] [Abstract][Full Text] [Related]
20. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
